MedImmune in-licenses AMG 108, targeting IL-1, from Amgen
This article was originally published in Scrip
Executive Summary
Amgen has granted AstraZeneca subsidiary MedImmune rights outside of Japan to develop and commercialise AMG 108, a human monoclonal antibody targeting the IL-1 pathway that has been tested in certain Phase I and Phase II trials.